**Specifications Table**TableSubject area*Biology*More specific subject area*Mdx mice model for Duchenne muscular dystrophy.*Type of data*Table, text file, graph*How data was acquired*2DE gels were analyzed with Progenesis SameSpots software v4.0 (Nonlinear Dynamics, UK). MS and MSMS data were obtained with Ultraflex III MALDI- TOF/TOF mass spectrometer (Bruker Daltonics)*Data format*Analyzed*Experimental factors*Effect of chronic exercise on muscle protein abundance in mdx mice model for Duchene muscular dystrophy. Modulation by two natural compounds apocynin and taurine*Experimental features*Animal model. Male mdx mice divided in:-sedentary mdx (mdx) mice-exercised mdx (mdx exe) mice- mdx exercised mice treated with taurine (mdx exe tau)-mdx exercised mice treated with apocynin (mdx exe apo)-C57/BL wild-type mice exercised (wt exe) and control (wt).Age-matched male wild-type mice (C57BL/10) has been used as referring phenotype. The training protocol consisted of a 30 min running on a horizontal treadmill (Columbus Instruments, USA) at 12 m/min, twice a week for at least 4 weeks. The doses of taurine and apocynin were 1 g/kg (orally) and 38 mg/kg (1.5 mmol/l in drinking water) respectively.Proteomics: 2DE and MS were used in order to identify differences in protein abundance between groups.*Data source location*Male mdx mice (C57BL/10ScSn-Dmdmdx/J from Jackson Laboratories) and C57/BL wild-type (wt) mice (from Jackson Laboratories)*Data accessibility*Data is provided by this article*

**Value of the data**•These data report for the first time the effect of chronic exercise protocol on protein abundance in mdx mice.•These data can provide information about muscle damage induced by an inappropriate exercise in dystrophic patients.•These data show the ability of taurine and apocynin to counteract some of exercise-induced protein alterations.

1. Data {#s0005}
=======

1.1. MS data {#s0010}
------------

97 differentially abundant spots were identified through the study published in [@bib1]. Among these, some spots showing low Mascot (PMF) score value or discrepancy between theoretical and calculated MW or pI, were further analyzed performing peptide sequencing by tandem mass spectrometry. MS/MS analysis was carried out by using an Ultraflex III MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) as described in Materials and Methods, and [Table 1](#t0005){ref-type="table"} reports detailed MALDI-TOF/TOF data. 12 spots show an experimental Mr different from expected. The sequence coverage of these spots is reported in [Table 2](#t0010){ref-type="table"}. The muscle protein LIM domain-binding protein 3 (LDB3) was found in three different spots showing a Mr lower than expected. This protein belongs to Z-disc proteins whose alteration was correlated with myofibrillar myopathies [@bib2]. Creatin kinase (Ckm) was found in six spots showing a Mr lower than expected.Table 1Differentially abundant protein spots that significantly differed between groups, identified by MALDI-TOF/TOF mass spectrometry analysis. The complete list of the proteins, identified by MALDI-TOF is reported in [@bib1].Table 1**Spot No**[a](#tbl1fna){ref-type="table-fn"}**Protein nameAC**[b](#tbl1fnb){ref-type="table-fn"}**Gene NameCellular component Go termTheoreticalObservedMascot search resultsPeptide Sequence**[g](#tbl1fng){ref-type="table-fn"}**Mr (kDa)/ pIMr (kDa)/ pI**[c](#tbl1fnc){ref-type="table-fn"}**Score**[d](#tbl1fnd){ref-type="table-fn"}**Matched Pept.**[e](#tbl1fne){ref-type="table-fn"}**Seq. coverage (%)**[f](#tbl1fnf){ref-type="table-fn"}**Sarcomere organization and muscle contraction**1LIM domain-binding protein 3Q9JKS4Ldb3Z-disc77.6/.7.930.1/9.7869/4517%\[21-32\] K.DFNMPLTISR.I\[37-69\] K.AAQSQLSQGDLVVAIDGVNTDTMTHLEAQNK.I\[70-83\] K.SASYNLSLTLQK.S3LIM domain-binding protein 3Q9JKS4Ldb3Z-disc77.6/.7.930.2/9.3768/3416%\[21-32\] K.DFNMPLTISR.I\[273-294\] R.ILAQMTGTEFMQDPDEEALR.R6Myozenin-1Q9JK37Myoz1Cytoskeleton31.4/8.631.7/7.912115/7767%\[42-57\] R.DVMLEELSLLTNR.G\[69-90\] K.FIYENHPDVFSDSSMDHFQK.F11Troponin T, fast skeletal muscleQ9QZ47Tnnt3Troponin complex32.2/5.331.5/7.88210/4333%\[61-76\] K.IPEGEKVDFDDIQK.K\[159-175\] K.ALSSMGANYSSYLAK.A12Troponin T, fast skeletal muscleQ9QZ47Tnnt3Troponin complex32.2/5.331.9/9.2748/2726%\[61-76\] K.IPEGEKVDFDDIQK.K\[159-175\] K.ALSSMGANYSSYLAK.A13Myosin regulatory light chain 2, skeletal muscle isoformP97457MylpfMyosin complex19/4.816.1/4.88810/4263%\[31-42\] K.EAFTVIDQNR.D\[41-52\] R.DGIIDKEDLR.D\[63-73\] K.NEELDAMMK.E\[92-106\] K.GADPEDVITGAFK.V16Myosin regulatory light chain 2, skeletal muscle isoformP97457MylpfMyosin complex19/4.817.1/4.9726/3637%\[31-42\] K.EAFTVIDQNR.D\[41-52\] R.DGIIDKEDLR.D\[92-106\] K.GADPEDVITGAFK.V23Actin, alpha skeletal muscle and Actin, alpha cardiac muscle1P68134 and P68033Acta1 and Actc1Cytoskeleton42.3/5.242.4/5.27214/3244%\[97-116\] R.VAPEEHPTLLTEAPLNPK.A\[240-257\] K.SYELPDGQVITIGNER.FProteasome complex89.9/5.142.4/5.2738/3027%\[25-46\] R.LIVDEAINEDNSVVSLSQPK.MTransitional endoplasmic reticulum ATPase (mix)^¤^Q01853Vcp\[295-313\] K.NAPAIIFIDELDAIAPK.R**Metabolism***(Glucose metabolism)*30Fructose-bisphosphate aldolase AP05064Aldoacytoplasm39.7/8.330.4/7.1606/2516%\[28-43\] K.GILAADESTGSIAK.R\[111-135\] K.GVVPLAGTNGETTTQGLDGLSER.C\[173-201\] R.YASICQQNGIVPIVEPEILPDGDHDLK.R34Triosephosphate isomeraseP17751Tpi1cytoplasm32.7/5.525/6.7918/2634%\[56-65\] K.FFVGGNWK.M\[150-163\] R.HVFGESDELIGQK.V\[256-270\] R.IIYGGSVTGATCK.E37Beta-enolaseP21550Eno3cytoplasm47.3/6.746.6/6.3958/2223%\[15-29\] R.GNPTVEVDLHTAK.G\[239-254\] K.VVIGMDVAASEFYR.N*(Respiratory chain complex)*48NADH dehydrogenase \[ubiquinone\] flavoprotein 2, mitochondrialQ9D6J6Ndufv2mitochondrion27.6/723.9/5.4718/3238%\[238-247\] K.GPGFGVQAGL.\[110-124\] R.VYEVATFYTMYNR.K\[41-61\] R.DTPENNPDTPFDFTPENYK.R51ATP synthase subunit alpha, mitochondrialQ03265Atp5a1mitochondrion59.8/9.2222.5/6.6727/2217%\[334-348\] R.EAYPGDVFYLHSR.LEnergy transfert55Creatine kinase M-typeP07310Ckmcytoplasm43.2/6.624.3/6.3617/2021%\[116-131\] K.GGDDLDPNYVLSSR.V\[156-171\] K.LSVEALNSLTGEFK.G57Creatine kinase M-typeP07310CkmCytoplasm43.2/6.629/6.66610/3927%\[116-131\] K.GGDDLDPNYVLSSR.V\[156-171\] K.LSVEALNSLTGEFK.G58Creatine kinase M-typeP07310CkmCytoplasm43.2/6.629.7/6.6617/3521%\[156-171\] K.LSVEALNSLTGEFK.G\[210-215\] R.DWPDAR.G\[223-237\] K.SFLVWVNEEDHLR.V60Creatine kinase M-typeP07310CkmCytoplasm43.2/6.617.4/7.9689/3429%\[259-267\] K.IEEIFKK.A\[269-381\] K.GQSIDDMIPAQK.\[341-359\] R.LGSSEVEQVQLVVDGVK.L70Adenylate kinase isoenzyme 1Q9R0Y5Ak1Cytoplasm21.6/5.721.5/5.3585/2036%\[9--22\] K.IIFVVGGPGSGK.G\[31-45\] K.YGYTHLSTGDLLR.A71Adenylate kinase isoenzyme 1Q9R0Y5Ak1Cytoplasm21.6/5.722/5.510411/4055%\[9--22\] K.IIFVVGGPGSGK.G\[131-139\] K.RGETSGR.V\[139-148\] R.VDDNEETIKK.RTransport87Voltage-dependent anion-selective channel protein 1Q60932Vdac1Mitochondrion32.5/8.529.8/8.67438%6/21\[109-123\] K.LTFDSSFSPNTGK.K\[87-107\]K.WNTDNTLGTEITVEDQLAR.G\[250-270\]K.VNNSSLIGLGYTQTLKPGIK.L[^1][^2][^3][^4][^5][^6][^7]Table 2Sequence coverage (in bold) of identified proteins that show an experimental Mr different from expected.Table 2**Spot No**[a](#tbl2fna){ref-type="table-fn"}**AC**[b](#tbl2fnb){ref-type="table-fn"}**Gene Name**[c](#tbl2fnc){ref-type="table-fn"}**Sequence coverage**[d](#tbl2fnd){ref-type="table-fn"}**Theoretical**[e](#tbl2fne){ref-type="table-fn"}**ObservedMr (kDa)/ pIMr (kDa)/ pI**[e](#tbl2fne){ref-type="table-fn"}1Q9JKS4Ldb3**1** MSYSVTLTGP GPWGFRLQGG K**DFNMPLTIS R**ITPGSK**AAQ SQLSQGDLVV**77.6/.7.930.1/9.7**51 AIDGVNTDTM THLEAQNK**IK SASYNLSLTL QK**SKRPIPIS TTAPPIQSPL101 PVIPHQK**DPA LDTNGSLATP SPSPEARASP GALEFGDTFS SSFSQTSVCS**151** PLMEASGPVL PLGSPVAKAS SEGAQGSVSP KVLPGPSQPR QYNNPIGLYS**201** AETLREMAQM YQMSLRGKAS GAGLLGGSLP VK**DLAVDSAS PVYQAVIKTQ251 SKPEDEADEW AR**RSSNLQSR SFR**ILAQMTG TEYMQDPDEE ALRR**SSTPIE**301** HAPVCTSQAT SPLLPASAQS PAAASPIAAS PTLATAAATH AAAASAAGPA**351** ASPVENPRPQ ASAYSPAAAA SPAPSAHTSY SEGPAAPAPK PRVVTTASIR**401** PSVYQPVPAS SYSPSPGANY SPTPYTPSPA PAYTPSPAPT YTPSPAPTYS**451** PSPAPAYTPS PAPNYTPTPS AAYSGGPSES ASRPPWVTDD SFSQKFAPGK**501** STTTVSKQTL PRGAPAYNPT GPQVTPLARG TFQRAERFPA SSRTPLCGHC**551** NNVIRGPFLV AMGRSWHPEE FNCAYCKTSL ADVCFVEEQN NVYCER**CYEQ601 FFAPICAK**CN TKIMGEVMHA LRQTWHTTCF VCAACKKPFG NSLFHMEDGE**651** PYCEKDYINL FSTKCHGCDF PVEAGDKFIE ALGHTWHDTC FICAVCHVNL**701** EGQPFYSKKD KPLCKKHAHA INV            2Q9JKS4Ldb3**1 MSYSVTLTGP GPWGFRLQGG KDFNMPLTIS R**ITPGSK**AAQ SQLSQGDLVV**77.6/.7.929.6/9.7**51 AIDGVNTDTM THLEAQNK**IK SASYNLSLTL QKSKRPIPIS TTAPPIQSPL**101** PVIPHQKDPA LDTNGSLATP SPSPEARASP GALEFGDTFS SSFSQTSVCS**151** PLMEASGPVL PLGSPVAKAS SEGAQGSVSP KVLPGPSQPR QYNNPIGLYS**201** AETLREMAQM YQMSLRGKAS GAGLLGGSLP VK**DLAVDSAS PVYQAVIKTQ251 SKPEDEADEW AR**RSSNLQSR SFR**ILAQMTG TEYMQDPDEE ALRR**SSTPIE**301** HAPVCTSQAT SPLLPASAQS PAAASPIAAS PTLATAAATH AAAASAAGPA**351** ASPVENPRPQ ASAYSPAAAA SPAPSAHTSY SEGPAAPAPK PRVVTTASIR**401** PSVYQPVPAS SYSPSPGANY SPTPYTPSPA PAYTPSPAPT YTPSPAPTYS**451** PSPAPAYTPS PAPNYTPTPS AAYSGGPSES ASRPPWVTDD SFSQKFAPGK**501** STTTVSKQTL PRGAPAYNPT GPQVTPLARG TFQRAERFPA SSRTPLCGHC**551** NNVIRGPFLV AMGRSWHPEE FNCAYCKTSL ADVCFVEEQN NVYCERCYEQ**601** FFAPICAKCN TKIMGEVMHA LRQTWHTTCF VCAACKKPFG NSLFHMEDGE**651** PYCEKDYINL FSTKCHGCDF PVEAGDKFIE ALGHTWHDTC FICAVCHVNL**701** EGQPFYSKKD KPLCKKHAHA INV            3Q9JKS4Ldb3**1** MSYSVTLTGP GPWGFRLQGG K**DFNMPLTIS R**ITPGSK**AAQ SQLSQGDLVV**77.6/.7.930.2/9.3**51 AIDGVNTDTM THLEAQNK**IK SASYNLSLTL QK**SKRPIPIS TTAPPIQSPL101 PVIPHQK**DPA LDTNGSLATP SPSPEARASP GALEFGDTFS SSFSQTSVCS**151** PLMEASGPVL PLGSPVAKAS SEGAQGSVSP KVLPGPSQPR QYNNPIGLYS**201** AETLREMAQM YQMSLRGKAS GAGLLGGSLP VK**DLAVDSAS PVYQAVIKTQ251 SKPEDEADEW AR**RSSNLQSR SFR**ILAQMTG TEYMQDPDEE ALRR**SSTPIE**301** HAPVCTSQAT SPLLPASAQS PAAASPIAAS PTLATAAATH AAAASAAGPA**351** ASPVENPRPQ ASAYSPAAAA SPAPSAHTSY SEGPAAPAPK PRVVTTASIR**401** PSVYQPVPAS SYSPSPGANY SPTPYTPSPA PAYTPSPAPT YTPSPAPTYS**451** PSPAPAYTPS PAPNYTPTPS AAYSGGPSES ASRPPWVTDD SFSQKFAPGK**501** STTTVSKQTL PRGAPAYNPT GPQVTPLARG TFQRAERFPA SSRTPLCGHC**551** NNVIRGPFLV AMGRSWHPEE FNCAYCKTSL ADVCFVEEQN NVYCERCYEQ**601** FFAPICAKCN TKIMGEVMHA LRQTWHTTCF VCAACKKPFG NSLFHMEDGE**651** PYCEKDYINL FSTKCHGCDF PVEAGDKFIE ALGHTWHDTC FICAVCHVNL**701** EGQPFYSKKD KPLCKKHAHA INV            51Q03265Atp5a1**1** MLSVRVAAAV ARALPRRAGL VSKNALGSSF VGARNLHASN TRLQKTGTAE59.8/9.2222.5/6.6**51** MSSILEERIL GADTSVDLEE TGRVLSIGDG IARVHGLRNV QAEEMVEFSS**101** GLKGMSLNLE PDNVGVVVFG NDKLIKEGDV VKRTGAIVDV PVGEELLGRV**151** VDALGNAIDG KGPIGSKTRR RVGLKAPGII PRISVREPMQ TGIKAVDSLV**201** PIGRGQRELI IGDRQTGKTS IAIDTIINQK RFNDGTDEKK KLYCIYVAIG**251** QKRSTVAQLV KRLTDADAMK YTIVVSATAS DAAPLQYLAP YSGCSMGEYF**301** RDNGKHALII YDDLSKQAVA YRQMSLLLRR PPGR**EAYPGD VFYLHSR**LLE**351** RAAKMNDSFG GGSLTALPVI ETQAGDVSAY IPTNVISITD GQIFLETELF**401** YK**GIRPAINV GLSVSR**VGSA AQTRAMKQVA GTMK**LELAQY REVAAFAQFG451 SDLDAATQQL LSR**GVRLTEL LK**QGQYSPMA IEEQVAVIYA GVR**GYLDKLE**501** PSKITK**FENA FLSHVISQHQ SLLGNIR**SDG KISEQSDAKL KEIVTNFLAG**551** FEP            55P07310Ckm**1 MPFGNTHNKF K**LNYKPQEEY PDLSKHNNHM AK**VLTPDLYN K**LRDKETPSG43.2/6.624.3/6.3**51** FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFK**DLFD PIIQDR**HGGY**101** KPTDKHKTDL NHENLK**GGDD LDPNYVLSSR** VRTGRSIK**GY TLPPHCSR**GE**151** RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP**201** LLLASGMAR**D WPDARGIWHN DNKSFLVWVN EEDHLR**VISM EKGGNMKEVF**251** RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA**301** NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV**351** QLVVDGVKLM VEMEKKLEKG QSIDDMIPAQ K            56P07310Ckm**1 MPFGNTHNKF KLNYKPQEEY PDLSK**HNNHM AKVLTPDLYN KLRDKETPSG43.2/6.628.8/6.6**51** FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFK**DLFD PIIQDR**HGGY**101** KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VR**TGRSIKGY TLPPHCSR**GE**151** RRAVEK**LSVE ALNSLTGEFK** GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP**201** LLLASGMARD WPDARGIWHN DNK**SFLVWVN EEDHLRVISM EK**GGNMKEVF**251** RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA**301** NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV**351** QLVVDGVKLM VEMEKKLEKG QSIDDMIPAQ K            57P07310Ckm**1 MPFGNTHNKF KLNYKPQEEY PDLSK**HNNHM AKVLTPDLYN KLRDKETPSG43.2/6.629/6.6**51** FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFK**DLFD PIIQDRHGGY101 KPTDKHK**TDL NHENLKGGDD LDPNYVLSSR VR**TGRSIKGY TLPPHCSR**GE**151** RRAVEK**LSVE ALNSLTGEFK** GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP**201** LLLASGMAR**D WPDAR**GIWHN DNK**SFLVWVN EEDHLRVISM EKGGNMK**EVF**251** RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA**301** NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV**351** QLVVDGVKLM VEMEKKLEKG QSIDDMIPAQ K            58P07310Ckm**1 MPFGNTHNKF KLNYKPQEEY PDLSK**HNNHM AK**VLTPDLYN K**LRDKETPSG43.2/6.629.7/6.6**51** FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFK**DLFD PIIQDR**HGGY**101** KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VRTGRSIK**GY TLPPHCSR**GE**151** RRAVEK**LSVE ALNSLTGEFK** GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP**201** LLLASGMARD WPDARGIWHN DNK**SFLVWVN EEDHLR**VISM EKGGNMKEVF**251** RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA**301** NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV**351** QLVVDGVKLM VEMEKKLEKG QSIDDMIPAQ K            59P07310Ckm**1 MPFGNTHNKF KLNYKPQEEY PDLSK**HNNHM AKVLTPDLYN KLRDKETPSG43.2/6.624.4/6.5**51** FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFK**DLFD PIIQDR**HGGY**101** KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VRTGRSIK**GY TLPPHCSR**GE**151** RRAVEK**LSVE ALNSLTGEFK** GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP**201** LLLASGMARD WPDARGIWHN DNKSFLVWVN EEDHLR**VISM EKGGNMK**EVF**251** RRFCVGLQKI EEIFKKAGHP FMWNEHLGYV LTCPSNLGTG LRGGVHVKLA**301** NLSKHPKFEE ILTRLRLQKR GTGGVDTAAV GAVFDISNAD RLGSSEVEQV**351** QLVVDGVKLM VEMEKKLEKG QSIDDMIPAQ K            60P07310Ckm**1 MPFGNTHNKF K**LNYKPQEEY PDLSKHNNHM AK**VLTPDLYN K**LRDKETPSG43.2/6.617.4/7.9**51** FTLDDVIQTG VDNPGHPFIM TVGCVAGDEE SYTVFKDLFD PIIQDRHGGY**101** KPTDKHKTDL NHENLKGGDD LDPNYVLSSR VRTGRSIKGY TLPPHCSRGE**151** RRAVEKLSVE ALNSLTGEFK GKYYPLKSMT EQEQQQLIDD HFLFDKPVSP**201** LLLASGMAR**D WPDAR**GIWHN DNK**SFLVWVN EEDHLR**VISM EKGGNMKEVF**251** RRFCVGLQKI EEIFKK**AGHP FMWNEHLGYV LTCPSNLGTG LR**GGVHVKLA**301** NLSKHPK**FEE ILTR**LRLQK**R GTGGVDTAAV GAVFDISNAD RLGSSEVEQV351 QLVVDGVK**LM VEMEKKLEKG QSIDDMIPAQ K            90Q9R1S8Capn7**1** MDASALERDA VQFARLAVQR DHEGRYSEAV FYYK**EAAQAL IYAEMAGSSL**93.3/8.117.6/10.3**51 ERIQEK**INEY LERVQALHSA VQSK**STDPLK** SKHQLDLER**A HFLVTQAFDE101 DEKGNVEDAI ELYTEAVELC LK**TSSETADK TLQNKLKQLA RQALDRAEAL**151** SEPLTKPFCK LKSANMK**TKT PPVR**THFPLG PNPFVEKPQA FISPQSCDAQ**201** GQKYTAEEIE VLRTTSKING VEYVPFMSVD LRERFAYPMP FCDRLGKLPL**251** SPKQKTTFSK WVRPEDLTNN PTMIYTVSSF SIKQTIVSDC SFVASLAISA**301** AYERRFNKKL ITSIIYPQNK DGEPEYNPCG KYMVKLHLNG VPRKVIIDDQ**351** LPVDHKGELL CSYSNNKSEL WVSLIEK**AYM KVMGGYDFPG SNSNIDLHAL401 TGWIPERIAM HSDSQTFSKD NSFR**MLYQRF HKGDVLITAS TGVMTEAEGE**451** KWGLVPTHAY AVLDIREFKG LRFIQLKNPW SHLRWKGRYS ENDVKNWTPE**501** LQKYLNFDPR TAQKIDNGIF WISWDDLCQY YDVVYLSWNP ALFKESTCIH**551** STWDAKQGPV K**DAYSLANNP QYKLEVQCPQ GGAAVWVLLS R**HITDKDDFA**601** NNREFITMVV YKTDGKKVYY PADPPPYIDG IRINSPHYLT KIKLTTPGTH**651** TFTLVVSQYE KQNTIHYTVR VYSACSFTFS KIPSPYTLSK RINGKWSGQS**701** AGGCGNFQET HKNNPIYQFH IDKTGPLLIE LRGPR**QYSVG FEVVAVSIMG751 DPGPHGFQRK** SSGDYRCGFC YLELENIPAG IFNIIPSTFL PK**QEGPFFLD801 FNSTVPIK**TT QLQ            96Q80XQ2Tbc1d5**1** MYKSVSETRH PLQSEEQEVG IDPLFSYSNK TRGDLSQNGR GSNSTLDTEG92.3/6.335.1/6.6**51** TFNSYMKEWE ELFVNNNYLA TVRQKGINGQ LRSSRFRSIC WKLFLCVLPQ**101** DKSQWISKIK ELRAWYSSIK EIHITNPRKA AGQQDLMINN PLSQDEGSLW**151** NK**FFQDKELR SMIEQDVK**RT FPEMQFFQQE NVRKILTDVL FCYARENEQL**201** LYKQGMHELL APIIFTLHCD HQAFLHASES AQPSEEMKTL LNPEYLEHDA**251** YAMFSQLMET AEPWFSTFEH DGQKGKETLM APIPFARPQD LGPTVAIVTK**301** VNQIQDHLLK KHDIELYMHL NRLEIAPQIY GLRWVRLLFG REFPLQDLLV**351** VWDALFADSL NLSLVDYVFT AMLLYIRDAL ISSNYQTCLG LLMHYPIIGD**401** IHSLILKALF LRDPKRNPRP ATYQFHPNLD YYKARGADLM NKSRTNARGA**451** PLNIHKVSNS LINFGRK**LIS PASAPGSMGG PVPGNNSSSS FSAAIPTR**TS**501** TEAPRHHLLQ QQQQQQHQQQ QQQQPQQQQQ QHQQQQQQQR LMKSESMPVQ**551** LNKGQSSKTI SSSPSIESLP GGREFTGSPP PSATKKDSFF SNIAR**SRSHS601 K**TMGRKESEE ELEAQISFLQ GQLNDLDAMC K**YCAKVMDMH LVNIQDVVLQ651 ENLEK**EDQIL VSLAGLKQIK DILKGSLRFN QSQLEAGENE QITIADDHYC**701** SSGQDQGSQV PRAAKQASSE MPGCTGGTTP DDFILVSKED EGHRARGAFS**751** GQAQPLLTLR STSGK**SRAPA CSPLLFSDPL MGPASASASS SNPSSSPDDD801 SSK**ESGFTIV SPLDI[^8][^9][^10][^11][^12]

1.2. Apocynin and taurine modulate the effect of exercise on mdx mice muscle protein abundance {#s0015}
----------------------------------------------------------------------------------------------

[Fig. 1](#f0005){ref-type="fig"} reports 97 histograms representing the spot abundance, in each group analysed (mdx, mdx exe, mdx exe tau, mdx exe apo) evaluated by gel image analysis with ProgenesisSame Spot. Proteins are divided in categories according to their GO biological process. Protein spot abundance in wt mice was also evaluated as referring phenotype. [Fig. 2](#f0010){ref-type="fig"} summarizes the modulatory effects of taurine and apocynin.Fig. 1Histograms represent the abundance of each spot (normalized volume, arbitrary units) in all groups studies, namely mdx, mdx exe, mdx exe apo, mdx exe tau (indicated as mdx+apo and mdx+tau respectively) and wt, evaluated with Progenesis SameSpot software. All spots show a False Discovery Rate (FDR) ≤0.05. The significant differences between groups were calculated with GraphPad Prism v6.0 software, using Tukey correction for multiple comparison. Significant differences between groups are indicated by a line.Fig. 1Fig. 2Picture representing different abundant spots between mdx and mdx exe treated and untreated with compounds. Detailed data on spot differences were reported in table 4 of ref [@bib1].Fig. 2

1.3. Comparison with wt strain {#s0020}
------------------------------

[Table 3](#t0015){ref-type="table"} reports differentially abundant protein spots and relative fold changes, between mdx exe *vs* wt and mdx *vs* wt tibialis anterior muscles. In [Fig. 3](#f0015){ref-type="fig"}a diagram represents the relationships between these three groups. The protocol used for mdx training consisted of a 30 min running on a horizontal treadmill (Columbus Instruments, USA) at 12 m/min, twice a week for at least 4 weeks. This protocol causes significant weakness in the limb strength as measured by a grip strength meter [@bib3]. The *in vivo* weakness produced by such a protocol is observed exclusively in mdx mice with no similar effects in wild type mice [@bib4], [@bib5]. In fact, protocols used to induce training effects in wild types mice usually consist of continuous running at 20 m/min for at least 15 min using a treadmill slope of 10°, five days a week, for eight weeks [@bib6]. To exclude training effects in wt animals we checked the amount of selected proteins in wt animals subjected to the same exercise protocol of mdx mice. In particular, we analysed by western blot the amount of several proteins of glycolysis (all increased in mdx exe mice), oxophos proteins, and PGC-1-alpha and Sirt1 proteins. As shown in [Fig. 4](#f0020){ref-type="fig"} none difference is observed in the expression level of these proteins.Fig. 3Diagram representing the distribution of differences in spot abundance between groups: 27 protein spots differ exclusively between mdx exe and wt, 15 protein spots differ exclusively between mdx and wt and 7 spots are different from wt in both mdx and mdx exe.Fig. 3Fig. 4Histograms and representative immunoblot images of glycolytic enzymes: Aldoa, Tpi1 and Eno3 (panel A); PGC1-alpha and Sirt1 (panel B) and Oxphos complexes from wt and wt exe mice. (n=5; mean ± S.D.; t-test unpaired). Normalization of immunoblot was performed on Coomassie stained gel.Fig. 4Table 3Differentially abundant protein spots between mdx exe *vs* wt and mdx *vs* wt tibialis anterior muscles.Table 3**Spot NoProtein name**[a](#tbl3fna){ref-type="table-fn"}**fold change mdx*****vs*****wt**[a](#tbl3fna){ref-type="table-fn"}**fold change mdx exe vs wt***Sarcomere structure and muscle contraction*3LIM domain-binding protein 3ns1.54LIM domain-binding protein 3ns1.75LIM domain-binding protein 3ns1.86Myozenin-1ns1.47Troponin I, fast skeletal muscle-2.2ns8Troponin I, fast skeletal muscle-1.6-1.59Troponin I, fast skeletal muscle-1.8ns14Myosin regulatory light chain 2, skeletal muscle isoformns-2.115Myosin regulatory light chain 2, skeletal muscle isoformns-3.716Myosin regulatory light chain 2, skeletal muscle isoform-2.1-4.117Tropomyosin beta chain-2.3-2.818Tropomyosin alpha-1 chain-1.8-2.820Myosin light chain 1/3, skeletal muscle isoformns-2.923Actin, alpha skeletal muscle and Actin, alpha cardiac muscle1-1.4ns24Actin, alpha cardiac muscle 1-1.4-1.626Myotilinns1.727Myotilinns1.8    *Metabolism and energy transfer*30Fructose-bisphosphate aldolase Ans1.632Triosephosphate isomerase-1.53ns33Triosephosphate isomerase-1.4ns36Triosephosphate isomerase-1.52ns39Beta-enolase-1.4ns41UTP\--glucose-1-phosphate uridylyltransferasens1.342Fumarate hydratase, mitochondrialns1.443Fumarate hydratase, mitochondrialns1.344Malate dehydrogenase, mitochondrial-1.8ns46Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrialns1.549NADH dehydrogenase \[ubiquinone\] 1 beta subcomplex subunit 71.8ns50Cytochrome b-c1 complex subunit 1, mitochondrial-1.6-1.654Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrialns1.555Creatine kinase M-type-2ns56Creatine kinase M-typens1.757Creatine kinase M-type-2.5ns59Creatine kinase M-type1.8ns68Creatine kinase M-type-1.5ns69Nucleoside diphosphate kinase Bns3.770Adenylate kinase isoenzyme 1ns-2.6    *Others*72Alcohol dehydrogenase \[NADP(+)\]ns1.474Carbonic anhydrase 3ns1.475Carbonic anhydrase 3ns1.378Malate dehydrogenase, cytoplasmic1.4ns81Serotransferrin1.51.882Serotransferrinns1.79126 S protease regulatory subunit 8ns1.692Protein disulfide-isomerase A3ns1.593Peroxiredoxin-6-1.6ns94Electron transfer flavoprotein subunit alpha, mitochondrialns1.496TBC1 domain family member 5ns1.397Alpha-crystallin B chainns1.8[^13]

2. Experimental design, materials and methods {#s0025}
=============================================

The methodologies that allowed the data here presented are described in [@bib1] and in cited references. Here, only the protocol for MS/MS data is described.

Trypsin digests of some spots with low Mascot (PMF) score value or with discrepancy between theoretical and calculated MW or pI were further analyzed performing peptide sequencing by tandem mass spectrometry. MS/MS analysis was performed by using an Ultraflex III MALDI- TOF/TOF mass spectrometer (Bruker Daltonics). Two to four PMF peaks showing a high intensity were CID fragmented using Argon as collision gas, and MALDI-TOF/TOF tandem MS was performed in LIFT mode by software controlled data acquisition. Fragmented ions were analyzed using the Flex Analysis software v.3.0. The MS/MS database searching was carried out in the UniProtKB database using the on-line available MASCOT MS/MS ion search software. The following parameters were applied for database searching: taxonomy: *Mus musculus*, trypsin specificity, one missed cleavage allowed, peptide precursor mass tolerance: ±100 ppm, fragment mass tolerance: ±0.6 Da, peptide precursor charge state: +1, carbamidomethylation of cysteine as a fixed modification, oxidation of methionine as a possible modification. For protein identification, Mascot ion score, peptide coverage by "b" and "y" ions, and expected value were considered. We considered as significant, peptides with individual ion scores −10 \* Log\[P\], where P is the probability that the observed match is a random event, that indicated identity (p \< 0.05).

Transparency document. Supplementary material {#s0040}
=============================================

Supplementary material.

This work has been supported by Dutch Duchenne Parent Project (DPP-NL) 2015 and Italian PRIN n. 2015MJBEM2_005.

Supplementary data associated with this article can be found in the online version at [10.1016/j.dib.2018.03.037](http://dx.doi.org/10.1016/j.dib.2018.03.037){#ir0005a}.

[^1]: Spot numbers match those reported in the representative 2DE images shown in [Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"} in ref. [@bib1]

[^2]: Accession number in Swiss-Prot/UniprotKB.

[^3]: Based on the calculation using Progenesis SameSpots 4.0 software

[^4]: MASCOT MS score (Matrix Science, London, UK; http://www.matrixscience.com). MS matching score greater than 56 was required for a significant MS hit (*p*-value\<0.05).

[^5]: Number of matched peptides correspond to peptide masses matching the top hit from Ms-Fit PMF, searched peptide are also reported.

[^6]: Sequence coverage = (number of the identified residues/total number of amino acid residues in the protein sequence) x100%.

[^7]: Peptide sequence obtained by Maldi TOFTOF analysis using an Ultraflex III MALDI- TOF/TOF mass spectrometer (Bruker Daltonics).

[^8]: Spot numbers match those reported in the representative 2DE images shown in [Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"} in ref. [@bib1]

[^9]: Accession number in Swiss-Prot/UniprotKB.

[^10]: Sequence coverage refers to the identified peptides of the protein sequence (bold letters).

[^11]: Theoretical molecular mass (Mr) and isoelectric point (pI) according to protein sequence.

[^12]: Molecular mass (Mr) and isoelectric point (pI) based on the calculation using software Progenesis SameSpots

[^13]: Fold change was calculated dividing the average of %V of mdx or mdx exe by the average of %V of wt (V =volume=integration of the optical density over the spot area; %V = V single spot/V total spots included in the reference gel).
